LA Times: Supreme Court spurns challenge to stem cell research
By David G. Savage
The Los Angeles Times
January 7, 2013
WASHINGTON -- The Supreme Court has turned away a challenge to President Obama’s policy of expanding government-funded research using embryonic stem cells that scientists say may offer hope for new treatments for spinal injuries and Parkinson’s disease.
The court’s action brings a quiet end to a lawsuit that briefly threatened to derail all funding for such research.
A federal judge in Washington in 2010 ordered the National Institutes of Health to halt funding of the research, citing a long-standing congressional ban on spending for research in which “human embryos are destroyed.”
But an appeals court overturned that order and ruled last year that the ban applied only to research which destroyed human embryos so as to obtain stem cells.
President George W. Bush in 2001 had allowed limited research on several stem cell lines that were already in existence. Upon taking office in 2009, President Obama went further and said NIH could conduct “scientifically worthy human stem cell research to the extent permitted by law.” Under guidelines issued by NIH, researchers can used stem line cells derived from donated frozen embryos that are no longer needed for fertility treatments.
The three-judge panel that upheld the Obama administration’s guidelines was made up Chief Judge David Sentelle, a Reagan appointee; Judge Karen Henderson, appointed by President George H.W. Bush; and Judge Janice Rogers Brown, an appointee of President George W. Bush.
Two researchers who work with adult stem lines, including Dr. James Sherley of the Boston Biomedical Research Institute, brought the lawsuit. They were represented by several groups, including the Law of Life Project. Samuel Casey, the group’s general counsel, called the human stem cell research “an ethical tragedy as well as a waste of the taxpayer’s money.”
They appealed to the high court in the fall, but the justices denied the appeal without comment or dissent in the case, Sherley v. Sebelius.
Stem cell symposium set for Sept. 19 in Ann Arbor
Dr. Eva Feldman will be among the speakers at the one-day event, which focuses on cutting-edge developments in stem-cell biology, epigenetics and regneratrive medicine.
Click here for details and registration.
New Emerging Scholar named
Scott Tomlins, M.D., an assistant profesor of pathology at U-M, has been designated the A. Alfred Taubman Emerging Scholar. Dr. Tomlins is an expert in prostate cancer research.
People who care
Institute welcomes new gift officer
Maria Muller has been appointed to work with connect donors with funding opportunities at the Taubman Institute.
Click here to read more.
news & events
Institute symposium set for Oct. 10
The A. Alfred Taubman Medical Research Institute will award the 2014 $100,000 Taubman Prize for Excellence in Translational Medical Science at its 7th annual symposium at 10 a.m. on Oct. 10.
Dr. Carl June, a physician-scientist who developed a personalized immunotherapy for leukemia using patients’ own T cells, will receive the honor and deliver the symposium's keynote address.
Click here for symposium details.
Drug cuts risk of bone-marrow transplant side effect
Taubman Emerging Scholar Sung Won Choi, M.D., is the lead author of a new study that finds a new way to help prevent graft-vs-host disease in cancer patients receiving bone-marrow transplants.
Study: Two types of cancer stem cells lead to metastasis
Breast cancer stem cells exist in two different states and each state plays a role in how cancer spreads, according to a new study published by Taubman Senior Scholar Dr. Max Wicha.